| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Streptococcus growth can be inhibited by Penicillin V (0.002-8.0 mg/L) at a minimum inhibitory concentration (MIC) of 0.004-0.008 mg/L[2]. With a MIC90 of 8 mg/L, penicillin V (0.002-8.0 mg/L) can stop Clostridium difficile from growing[3]. With a MIC of 0.016 mg/L, Penicillin V (0.004-0.063 mg/L; 18 h) suppresses the development of Staphylococcus aureus [4].
|
|---|---|
| ln Vivo |
In mouse thigh muscles, Penicillin V (0.063-0.25 mg/kg; single subcutaneous injection) inhibits Staphylococcus aureus growth [4]. Rats with acute suppurative otitis media (AOM) can avoid fulminant infection by administering Penicillin V (100 mg/kg) orally once a day for five days [5]. The mean area under the curve (AUC) for penicillin V (2 mg/kg; single subcutaneous injection) is 0.47 mg/L·h, and its plasma half-life is 61 minutes[4][4].
|
| Animal Protocol |
Animal/Disease Models: Specific pathogen-free (SPF) male Swiss mice (20-25 g) inoculated with Staphylococcus aureus [4]
Doses: 0.063, 0.13, 0.25 mg/kg Route of Administration: Single subcutaneous injection Experimental Results: Reduction in CFU number ( 1.34 × 107 counts/mL) compared with the control at a dose of 0.25 mg/kg (3.5 × 107 counts/mL). |
| References |
[1]. Sabath LD. Et, al. Phenoxymethylpenicillin (penicillin V) and phenethicillin. Med Clin North Am. 1970 Sep;54(5):1101-11.
[2]. Kamme C, et, al. In vitro effect on group A streptococci of loracarbef versus cefadroxil, cefaclor and penicillin V. Scand J Infect Dis. 1993;25(1):37-42. [3]. Norén T, et, al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect. 2010 Aug;16(8):1104-10. [4]. Overbosch D, et, al. Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin. Br J Clin Pharmacol. 1985 May;19(5):657-68. [5]. Hermansson A, et, al. Prevention of experimental acute otitis media with penicillin V. Acta Otolaryngol. Jan-Feb 1990;109(1-2):119-23. |
| Molecular Formula |
C16H17KN2O5S
|
|---|---|
| Molecular Weight |
388.4793
|
| Exact Mass |
388.0495
|
| CAS # |
132-98-9
|
| Related CAS # |
Penicillin V-d5;1356837-87-0;Penicillin V;87-08-1;Penicillin V-13C6 potassium;Penicillin V Potassium-d5;2699607-22-0
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
S1C(C([H])([H])[H])(C([H])([H])[H])[C@]([H])(C(=O)O[H])N2C([C@]([H])([C@@]12[H])N([H])C(C([H])([H])OC1C([H])=C([H])C([H])=C([H])C=1[H])=O)=O
|
| Synonyms |
Penicillin V potassium HSDB 6315 Penicillin VK
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12 mg/mL (~30.89 mM)
H2O : ~6 mg/mL (~15.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.2 mg/mL (3.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.2 mg/mL (3.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.2 mg/mL (3.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (257.41 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5741 mL | 12.8707 mL | 25.7414 mL | |
| 5 mM | 0.5148 mL | 2.5741 mL | 5.1483 mL | |
| 10 mM | 0.2574 mL | 1.2871 mL | 2.5741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
